RSS   Newsletter   Contact   Advertise with us
Post Online Media
ImmunoMet Therapeutics appoints two directors POST Online Media

ImmunoMet Therapeutics appoints two directors

Staff Writer | Houston, Tx., USA | Wednesday November 29, 2017 5:45AM ET
ImmunoMet TherapeuticsNovember 29, 2017, Houston, Tx., USA - ImmunoMet Therapeutics, a private biotechnology company, announced the appointment of Briggs W. Morrison and Paul Lammers to its board of directors.
Briggs W. Morrison currently serves as the CEO and is a member of the board of directors of Syndax Pharmaceuticals, Inc.

Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.

Prior to joining Syndax and MPM Capital, Dr. Morrison served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, from January 2012 to June 2015, leading the company's global, late-stage development organization and serving as a member of the AstraZeneca senior executive team.

Dr. Morrison previously held a number of positions at Pfizer Inc., from 2007 to January 2012, that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business.

Dr. Morrison also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs.

He was chairman of the board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, from 2014 to 2015, a member of the executive committee of the Clinical Trials Transformation Initiative (CTTI) sponsored by FDA, and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety) and Oncorus, Inc.

Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.

Paul Lammers currently serves as an independent biotech consultant and Scientific Advisor to life sciences companies.

In August 2017, Dr. Lammers successfully completed a reverse merger of Mirna Therapeutics, the company he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA.

In 2009, Dr. Lammers served as President of Repros Therapeutics, The Woodlands, Texas.

Prior to Repros Therapeutics, he served six years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of German Pharmaceutical company, Merck KgA.

Dr. Lammers began his pharmaceutical career at Organon in the Netherlands, and is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of continuing medical education (CME) programs for medical scientists and healthcare professionals.

Dr. Lammers received his Medical Degree and Masters of Science degree from the Catholic University in Nijmegen, The Netherlands.